Successfully led multiple formulation programs across all phases of the product development cycle.
Led regulatory strategy development and implementation efforts culminating in the first US and EU marketing approvals for small pharma company.
Advanced from Harvard Medical School post-doctoral fellowship to lead multiple preclinical & clinical virology studies.
Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.
Secured $150M financing and prepared Peloton Therapeutics for IPO — laying groundwork for Merck & Co. acquisition.